



Clinical and Pathologic Response to Therapy in Gastrointestinal Oncology

Guest Editors:

Dr. Daniel A. Anaya

Moffitt Cancer Center, Tampa, FL,
USA

Dr. Andrew J. Sinnamon

Moffitt Cancer Center, Tampa, FL,
USA

Deadline for manuscript
submissions:

closed (31 July 2024)

Message from the Guest Editors

Dear Colleagues,

With a growing focus on multimodality therapy for a variety of gastrointestinal cancers, there has been a movement to emphasize therapies in the neoadjuvant setting. One major potential advantage of this approach is the ability to study treatment effects of therapies for tumors in their original location. However, with an ever-expanding array of novel treatments, including, but not limited to, immune and targeted therapies, the study of treatment response becomes increasingly complex. Research efforts are needed to improve our understanding of tumor response biology and the subsequent prognostic and therapeutic implications. This Special Issue focuses on recent efforts (original research and reviews) to study tumor responses to oncologic therapy across gastrointestinal oncology.

Dr. Daniel A. Anaya

Dr. Andrew J. Sinnamon

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)